SERDs in Development for the Treatment of Breast Cancer

Kevin Kalinsky, MD, MS, associate professor, Department of Hematology and Medical Oncology at Emory University School of Medicine, and the Louisa and Rand Glenn Family chair in Breast Cancer Research, director of the Glenn Family Breast Center, and director of the Breast Medical Oncology at Winship Cancer Institute, discussed selective estrogen receptor downregulators (SERDs) being explored for the treatment of breast cancer.

Transcription:

0:07 | Right now in clinical practice, the only approved selective estrogen receptor down regulator or SERD is fulvestrant [Faslodex]. At San Antonio, we saw the results of the first randomized study with an oral SERD. This was the EMERALD study or assessment versus physician choice, hormonal therapy. And we saw there was a statistically significant improvement in outcomes such as progression-free survival, particularly for those who have ESR1 mutations, which we're seeing [in] about a third of patients with hormone receptor-positive or negative disease, which those tumors have progressed on endocrine therapy.

0:44 | But there are a smattering of other SERDs that are coming down the pike. [These are] randomized studies, including studies with amcenestrant.

1:03 | So, this field is rapidly moving forward, not just anticipated in the metastatic setting, but also in the early-stage setting. And there are some studies that are ongoing and should be opening for patients in the early setting with oral SERDs as well as other hormonal therapies.